The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.
about
Advances in anticancer immunotoxin therapyPentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.Immunopathological changes in the brain of immunosuppressed mice experimentally infected with Toxocara canis.High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.MHC-mismatched mixed chimerism augments thymic regulatory T-cell production and prevents relapse of EAE in mice.A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.Immunotoxin Therapy for Lung Cancer.Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation.Rapamycin-resistant effector T-cell therapy.Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment.
P2860
Q28085551-2F55F24D-5FFC-4AD2-8594-E4A6D3C0F16CQ35023967-053B12D5-FD97-4B3D-90E7-274FC605D77EQ35262181-7D8F1DE1-947C-46A5-BA3D-0AC624C83D27Q36117735-9D55B1F5-5158-415F-8791-2B422B85CFCAQ36341861-FE0F6C5F-0BC1-4ED3-8A6D-7011C84FC72BQ36435150-7CDF0EB4-6350-4902-8979-805F3C39C657Q37206443-3CDB8621-4BA4-434D-86AA-42B2F279B036Q37397003-FE605C33-B706-4980-BBBF-FA44FDAD3917Q37684156-10675E48-3834-4C52-B2E3-5A1B8C623CADQ38105635-64E2B3E4-9B00-467F-B596-B73B863195D0Q38170502-13788ACF-F919-4DF1-93A0-9AD9815E1FB3Q52603959-31FE83AD-ADA1-4DC1-BC80-8F4FAF8CE717
P2860
The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@ast
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@en
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@nl
type
label
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@ast
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@en
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@nl
prefLabel
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@ast
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@en
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@nl
P2093
P2860
P1476
The pentostatin plus cyclophos ...... ne marrow allograft rejection.
@en
P2093
Daniel H Fowler
Jacopo Mariotti
Jason Foley
Justin Taylor
Kaitlyn Ryan
Miriam E Mossoba
Nicole Buxhoeveden
Paul R Massey
Shoba Amarnath
Tania C Felizardo
P2860
P304
P356
10.1016/J.BBMT.2010.11.029
P577
2010-12-03T00:00:00Z